KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:待检查 入排置信度 0.98

Survival Outcomes with Cilta-cel Versus Conventional Treatment Regimens for Patients with Lenalidomide-Refractory Multiple Myeloma Using Inverse Probability of Treatment Weighting.

Rafael Fonseca, Joris Diels, Francesca Ghilotti, João Mendes, Sandra Van Hoorenbeeck, Seina Lee, Jordan M Schecter, Nikoletta Lendvai, Nitin Patel, Ana Triguero, Winfried Alsdorf, Niels W C J van de Donk, Margherita Ursi

Adv Ther 42(9) 4418-4431

PMID40613875
PMCIDPMC12394250
DOI10.1007/s12325-025-03278-5
发表日期2025-07-04
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
AI 判定该论文不进入自动 KM 提取:This is an indirect comparison (meta-analysis-like) using pooled individual patient data from multiple prior trials (CARTITUDE-4, CASTOR, CANDOR, APOLLO) via statistical adjustment (IPTW), not a direct report of a single human Phase III randomized controlled trial.
摘要

摘要

INTRODUCTION: The phase 3 CARTITUDE-4 trial demonstrated superiority of ciltacabtagene autoleucel (cilta-cel) over daratumumab, pomalidomide and dexamethasone, or pomalidomide, bortezomib and dexamethasone, in lenalidomide-refractory patients with relapsed/refractory multiple myeloma (RRMM) who received 1-3 prior lines of therapy. The comparative efficacy of cilta-cel was previously evaluated against other common regimens. Here, we present an updated comparative efficacy assessment, including OS, between cilta-cel (CARTITUDE-4 34-month median follow-up) and common regimens. METHODS: Individual patient data were available from CARTITUDE-4 (cilta-cel), CASTOR (daratumumab, bortezomib and dexamethasone [DVd]), CANDOR (daratumumab, carfilzomib and dexamethasone [DKd] and carfilzomib and dexamethasone [Kd]) and APOLLO (pomalidomide and dexamethasone [Pd]). Inverse probability of treatment weighting (IPTW) was used to adjust for key baseline patient characteristic imbalances. Relative efficacies were estimated with response rate ratios and 95% confidence intervals (CIs) for response rates, with hazard ratios (HRs) and 95% CIs for PFS and OS. Sensitivity analyses using alternative statistical approaches were explored. RESULTS: After excluding 53 patients with prior anti-CD38 therapy exposure, cilta-cel (n = 155) was compared with DVd (n = 44), DKd (n = 98), Kd (n = 46) and Pd (n = 92). Baseline covariates were generally well balanced across cohorts after IPTW. Cilta-cel showed significant improvements in PFS (HR 0.21-0.58; p ≤ 0.01) and OS (HR 0.31-0.55; p < 0.05) vs all regimens. With longer follow-up, the relative benefit of cilta-cel versus other regimens further increased on deeper levels of response. Although all results, except ORR, significantly favored cilta-cel, the DKd comparison provided the most conservative estimates. CONCLUSION: This updated analysis confirms previously observed significant superiority of PFS and response outcomes of cilta-cel while showing significant OS benefit compared with common regimens for this population. These findings support cilta-cel as an effective treatment for lenalidomide-refractory RRMM patients as early as second line. TRIAL REGISTRATION: CARTITUDE-4 ClinicalTrials.gov ID: NCT04181827.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。